Trial Profile
Safety and efficacy of Sofosbuvir Plus Daclatasvir Versus Sofosbuvir Plus Ribavirin in Patients with Chronic C Hepatitis Genotype 2 Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases